Использование генераторного оборудования электростанций в качестве синхронных компенсаторов

Consider the set of all sequences of n outcomes, each taking one of m values, whose frequency vectors satisfy a set of linear constraints. If m is fixed while n increases, most sequences that satisfy the constraints result in frequency vectors whose entropy approaches that of the maximum entropy vector satisfying the constraints. This well-known entropy concentration phenomenon underlies the maximum entropy method. Existing proofs of the concentration phenomenon are based on limits or asymptotics and unrealistically assume that constraints hold precisely, supporting maximum entropy inference more in principle than in practice. We present, for the first time, non-asymptotic, explicit lower bounds on n for a number of variants of the concentration result to hold to any prescribed accuracies, with the constraints holding up to any specified tolerance, considering the fact that allocations of discrete units can satisfy constraints only approximately. Again unlike earlier results, we measure concentration not by deviation from the maximum entropy value, but by the ℓ1 and ℓ2 distances from the maximum entropy-achieving frequency vector. One of our results holds independently of the alphabet size m and is based on a novel proof technique using the multi-dimensional Berry-Esseen theorem. We illustrate and compare our results using various detailed examples

On the use of intelligent models towards meeting the challenges of the edge mesh

Nowadays, we are witnessing the advent of the Internet of Things (IoT) with numerous devices performing interactions between them or with their environment. The huge number of devices leads to huge volumes of data that demand the appropriate processing. The “legacy” approach is to rely on Cloud where increased computational resources can realize any desired processing. However, the need for supporting real-time applications requires a reduced latency in the provision of outcomes. Edge Computing (EC) comes as the “solver” of the latency problem. Various processing activities can be performed at EC nodes having direct connection with IoT devices. A number of challenges should be met before we conclude a fully automated ecosystem where nodes can cooperate or understand their status to efficiently serve applications. In this article, we perform a survey of the relevant research activities towards the vision of Edge Mesh (EM), i.e., a “cover” of intelligence upon the EC. We present the necessary hardware and discuss research outcomes in every aspect of EC/EM nodes functioning. We present technologies and theories adopted for data, tasks, and resource management while discussing how machine learning and optimization can be adopted in the domain

A Probabilistic Batch Oriented Proactive Workflow Management

Workflow management is a widely studied research subject due to its criticality for the efficient execution of various processing activities towards concluding innovative applications. The ultimate goal is to eliminate the required time for delivering the final outcome considering the dependencies between workflow’s tasks. In this paper, we enhance the decision making of a scheduler with a batch oriented approach to deal with multiple workflows. A probabilistic data oriented approach combined with an infrastructure oriented scheme is provided to pay attention on dynamic environments where the underlying data are continuously updated trying to minimize the network overhead for migrating data. Workflows are mapped to the available datasets according to their data requirements, then, we combine the outcome with an optimization model upon the time and cost requirements of every placement. The performance of our model is revealed by a high number of experiments depicting the advantages in the network overhead

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701